Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients
Purpose: We studied serum monocyte chemotactic protein-1 (MCP-1) levels in breast cancer patients in relationship to their clinicopathologic variables and immune response to a / neu E75 vaccine. Experimental Design: We measured MCP-1 levels in 32 / neu + breast cancer patients before and after vacci...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2006-01, Vol.12 (2), p.478-486 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 486 |
|---|---|
| container_issue | 2 |
| container_start_page | 478 |
| container_title | Clinical cancer research |
| container_volume | 12 |
| creator | DEHQANZADA, Zia A STORRER, Catherine E HUEMAN, Matthew T FOLEY, Rebecca J HARRIS, Katie A JAMA, Yusuf H KAO, Tzu-Cheg SHRIVER, Craig D PONNIAH, Sathibalan PEOPLES, George E |
| description | Purpose: We studied serum monocyte chemotactic protein-1 (MCP-1) levels in breast cancer patients in relationship to their clinicopathologic
variables and immune response to a / neu E75 vaccine.
Experimental Design: We measured MCP-1 levels in 32 / neu + breast cancer patients before and after vaccination with a / neu E75 peptide + granulocyte macrophage colony-stimulating factor vaccine. Clinical prognostic variables were collected. Vaccine-specific
immunologic responses were monitored.
Results: Serum MCP-1 levels >250 pg/mL (MCP-high) correlated with favorable prognostic variables. MCP-high patients compared with
MCP-low (50% increase in MCP-1 levels (response-high) had worse clinical
prognostic variables compared with patients with 30% postvaccination
MCP-1 increase also showed significant increases in E75-specific CD8 + T-cells (0.05% versus 0.38%; P = 0.03) in response to vaccination.
Conclusions: High serum MCP-1 levels in breast cancer patients correlate with favorable prognostic variables and increased preexisting
/ neu immunity. E75 vaccination induces the largest MCP-1 response in patients with unfavorable clinicopathologic variables. Therefore,
low serum MCP-1 levels may identify patients with worse prognosis and those most likely to benefit from this vaccination. |
| doi_str_mv | 10.1158/1078-0432.CCR-05-1425 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70696746</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70696746</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-ad3db408aa41041289926556bf566986ca5f9f261a5071441c0e43c25f8734843</originalsourceid><addsrcrecordid>eNqFkctu1DAUhiMEoqXwCCBvoBvc2o4vyRKillYaRDVctpbHOekYJXaxnVbzNLwqDjOoS1a2dL5zjv1_VfWakjNKRXNOiWow4TU767o1JgJTzsST6pgKoXDNpHha7v-Yo-pFSj8JoZwS_rw6opKzhrfkuPrdhRhhNNkFn9AG8gOAR18hzhP6HHywuwyo28IUsrHZWXQTQwbnMUUruIcxvUfd6LyzZlxKtz6khboscIilaHyPri7WmJ17mNEPY63zgNfLRujR9TTN3uUdch59jGBSRp3xFiK6KS8Cn9PL6tlgxgSvDudJ9f3y4lt3hVdfPl13H1bYcq4yNn3dbzhpjFl-SFnTtiUCITeDkLJtpDViaAcmqRFEUc6pJcBry8TQqJo3vD6p3u3n3sXwa4aU9eSShXE0HsKctCKylYrL_4JUcSVrukwUe9DGkFKEQd9FN5m405ToRaFe9OhFjy4KNRF6UVj63hwWzJsJ-seug7MCvD0AJpXYh1gSc-mRU4IK3rLCne65rbvdPrgI2v7NNkICE-1WU6aZ5qqp_wCHrrHz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17476314</pqid></control><display><type>article</type><title>Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>DEHQANZADA, Zia A ; STORRER, Catherine E ; HUEMAN, Matthew T ; FOLEY, Rebecca J ; HARRIS, Katie A ; JAMA, Yusuf H ; KAO, Tzu-Cheg ; SHRIVER, Craig D ; PONNIAH, Sathibalan ; PEOPLES, George E</creator><creatorcontrib>DEHQANZADA, Zia A ; STORRER, Catherine E ; HUEMAN, Matthew T ; FOLEY, Rebecca J ; HARRIS, Katie A ; JAMA, Yusuf H ; KAO, Tzu-Cheg ; SHRIVER, Craig D ; PONNIAH, Sathibalan ; PEOPLES, George E</creatorcontrib><description>Purpose: We studied serum monocyte chemotactic protein-1 (MCP-1) levels in breast cancer patients in relationship to their clinicopathologic
variables and immune response to a / neu E75 vaccine.
Experimental Design: We measured MCP-1 levels in 32 / neu + breast cancer patients before and after vaccination with a / neu E75 peptide + granulocyte macrophage colony-stimulating factor vaccine. Clinical prognostic variables were collected. Vaccine-specific
immunologic responses were monitored.
Results: Serum MCP-1 levels >250 pg/mL (MCP-high) correlated with favorable prognostic variables. MCP-high patients compared with
MCP-low (<250 pg/mL) patients showed statistically significant later onset of disease, earlier stage of disease, fewer nodal
metastasis, and less chemotherapy. MCP-high patients had increased levels of preexisting immunity when compared with MCP-low
patients (69% versus 21%; P = 0.02). However, MCP-low patients showed higher inducible levels of MCP-1 compared with MCP-high patients (median increase,
41% versus 0%; P = 0.001) after vaccination. Moreover, MCP-low patients with >50% increase in MCP-1 levels (response-high) had worse clinical
prognostic variables compared with patients with <50% increase (response-low). Response-high patients had statistically significant
more poorly differentiated tumors, later stage of disease, and higher percentage of large tumors. Patients with >30% postvaccination
MCP-1 increase also showed significant increases in E75-specific CD8 + T-cells (0.05% versus 0.38%; P = 0.03) in response to vaccination.
Conclusions: High serum MCP-1 levels in breast cancer patients correlate with favorable prognostic variables and increased preexisting
/ neu immunity. E75 vaccination induces the largest MCP-1 response in patients with unfavorable clinicopathologic variables. Therefore,
low serum MCP-1 levels may identify patients with worse prognosis and those most likely to benefit from this vaccination.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-05-1425</identifier><identifier>PMID: 16428490</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic agents ; Biological and medical sciences ; Biomarkers, Tumor - metabolism ; breast cancer ; Breast Neoplasms - immunology ; Breast Neoplasms - prevention & control ; Cancer Vaccines - therapeutic use ; Chemokine CCL2 - metabolism ; Disease Progression ; Female ; Granulocyte-Macrophage Colony-Stimulating Factor - immunology ; Granulocyte-Macrophage Colony-Stimulating Factor - metabolism ; Gynecology. Andrology. Obstetrics ; Humans ; Immunity, Cellular ; Immunoconjugates ; Lymph Nodes - immunology ; Lymph Nodes - metabolism ; Lymph Nodes - pathology ; Mammary gland diseases ; MCP-1 ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Peptide Fragments - immunology ; Pharmacology. Drug treatments ; Prognosis ; prognostic factors ; Receptor, ErbB-2 - metabolism ; Survival Rate ; tumor immunity ; Tumors</subject><ispartof>Clinical cancer research, 2006-01, Vol.12 (2), p.478-486</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-ad3db408aa41041289926556bf566986ca5f9f261a5071441c0e43c25f8734843</citedby><cites>FETCH-LOGICAL-c447t-ad3db408aa41041289926556bf566986ca5f9f261a5071441c0e43c25f8734843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17515492$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16428490$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DEHQANZADA, Zia A</creatorcontrib><creatorcontrib>STORRER, Catherine E</creatorcontrib><creatorcontrib>HUEMAN, Matthew T</creatorcontrib><creatorcontrib>FOLEY, Rebecca J</creatorcontrib><creatorcontrib>HARRIS, Katie A</creatorcontrib><creatorcontrib>JAMA, Yusuf H</creatorcontrib><creatorcontrib>KAO, Tzu-Cheg</creatorcontrib><creatorcontrib>SHRIVER, Craig D</creatorcontrib><creatorcontrib>PONNIAH, Sathibalan</creatorcontrib><creatorcontrib>PEOPLES, George E</creatorcontrib><title>Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Purpose: We studied serum monocyte chemotactic protein-1 (MCP-1) levels in breast cancer patients in relationship to their clinicopathologic
variables and immune response to a / neu E75 vaccine.
Experimental Design: We measured MCP-1 levels in 32 / neu + breast cancer patients before and after vaccination with a / neu E75 peptide + granulocyte macrophage colony-stimulating factor vaccine. Clinical prognostic variables were collected. Vaccine-specific
immunologic responses were monitored.
Results: Serum MCP-1 levels >250 pg/mL (MCP-high) correlated with favorable prognostic variables. MCP-high patients compared with
MCP-low (<250 pg/mL) patients showed statistically significant later onset of disease, earlier stage of disease, fewer nodal
metastasis, and less chemotherapy. MCP-high patients had increased levels of preexisting immunity when compared with MCP-low
patients (69% versus 21%; P = 0.02). However, MCP-low patients showed higher inducible levels of MCP-1 compared with MCP-high patients (median increase,
41% versus 0%; P = 0.001) after vaccination. Moreover, MCP-low patients with >50% increase in MCP-1 levels (response-high) had worse clinical
prognostic variables compared with patients with <50% increase (response-low). Response-high patients had statistically significant
more poorly differentiated tumors, later stage of disease, and higher percentage of large tumors. Patients with >30% postvaccination
MCP-1 increase also showed significant increases in E75-specific CD8 + T-cells (0.05% versus 0.38%; P = 0.03) in response to vaccination.
Conclusions: High serum MCP-1 levels in breast cancer patients correlate with favorable prognostic variables and increased preexisting
/ neu immunity. E75 vaccination induces the largest MCP-1 response in patients with unfavorable clinicopathologic variables. Therefore,
low serum MCP-1 levels may identify patients with worse prognosis and those most likely to benefit from this vaccination.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>breast cancer</subject><subject>Breast Neoplasms - immunology</subject><subject>Breast Neoplasms - prevention & control</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Chemokine CCL2 - metabolism</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Granulocyte-Macrophage Colony-Stimulating Factor - immunology</subject><subject>Granulocyte-Macrophage Colony-Stimulating Factor - metabolism</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunity, Cellular</subject><subject>Immunoconjugates</subject><subject>Lymph Nodes - immunology</subject><subject>Lymph Nodes - metabolism</subject><subject>Lymph Nodes - pathology</subject><subject>Mammary gland diseases</subject><subject>MCP-1</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Peptide Fragments - immunology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>prognostic factors</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Survival Rate</subject><subject>tumor immunity</subject><subject>Tumors</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctu1DAUhiMEoqXwCCBvoBvc2o4vyRKillYaRDVctpbHOekYJXaxnVbzNLwqDjOoS1a2dL5zjv1_VfWakjNKRXNOiWow4TU767o1JgJTzsST6pgKoXDNpHha7v-Yo-pFSj8JoZwS_rw6opKzhrfkuPrdhRhhNNkFn9AG8gOAR18hzhP6HHywuwyo28IUsrHZWXQTQwbnMUUruIcxvUfd6LyzZlxKtz6khboscIilaHyPri7WmJ17mNEPY63zgNfLRujR9TTN3uUdch59jGBSRp3xFiK6KS8Cn9PL6tlgxgSvDudJ9f3y4lt3hVdfPl13H1bYcq4yNn3dbzhpjFl-SFnTtiUCITeDkLJtpDViaAcmqRFEUc6pJcBry8TQqJo3vD6p3u3n3sXwa4aU9eSShXE0HsKctCKylYrL_4JUcSVrukwUe9DGkFKEQd9FN5m405ToRaFe9OhFjy4KNRF6UVj63hwWzJsJ-seug7MCvD0AJpXYh1gSc-mRU4IK3rLCne65rbvdPrgI2v7NNkICE-1WU6aZ5qqp_wCHrrHz</recordid><startdate>20060115</startdate><enddate>20060115</enddate><creator>DEHQANZADA, Zia A</creator><creator>STORRER, Catherine E</creator><creator>HUEMAN, Matthew T</creator><creator>FOLEY, Rebecca J</creator><creator>HARRIS, Katie A</creator><creator>JAMA, Yusuf H</creator><creator>KAO, Tzu-Cheg</creator><creator>SHRIVER, Craig D</creator><creator>PONNIAH, Sathibalan</creator><creator>PEOPLES, George E</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20060115</creationdate><title>Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients</title><author>DEHQANZADA, Zia A ; STORRER, Catherine E ; HUEMAN, Matthew T ; FOLEY, Rebecca J ; HARRIS, Katie A ; JAMA, Yusuf H ; KAO, Tzu-Cheg ; SHRIVER, Craig D ; PONNIAH, Sathibalan ; PEOPLES, George E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-ad3db408aa41041289926556bf566986ca5f9f261a5071441c0e43c25f8734843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>breast cancer</topic><topic>Breast Neoplasms - immunology</topic><topic>Breast Neoplasms - prevention & control</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Chemokine CCL2 - metabolism</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Granulocyte-Macrophage Colony-Stimulating Factor - immunology</topic><topic>Granulocyte-Macrophage Colony-Stimulating Factor - metabolism</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunity, Cellular</topic><topic>Immunoconjugates</topic><topic>Lymph Nodes - immunology</topic><topic>Lymph Nodes - metabolism</topic><topic>Lymph Nodes - pathology</topic><topic>Mammary gland diseases</topic><topic>MCP-1</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Peptide Fragments - immunology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>prognostic factors</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Survival Rate</topic><topic>tumor immunity</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DEHQANZADA, Zia A</creatorcontrib><creatorcontrib>STORRER, Catherine E</creatorcontrib><creatorcontrib>HUEMAN, Matthew T</creatorcontrib><creatorcontrib>FOLEY, Rebecca J</creatorcontrib><creatorcontrib>HARRIS, Katie A</creatorcontrib><creatorcontrib>JAMA, Yusuf H</creatorcontrib><creatorcontrib>KAO, Tzu-Cheg</creatorcontrib><creatorcontrib>SHRIVER, Craig D</creatorcontrib><creatorcontrib>PONNIAH, Sathibalan</creatorcontrib><creatorcontrib>PEOPLES, George E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DEHQANZADA, Zia A</au><au>STORRER, Catherine E</au><au>HUEMAN, Matthew T</au><au>FOLEY, Rebecca J</au><au>HARRIS, Katie A</au><au>JAMA, Yusuf H</au><au>KAO, Tzu-Cheg</au><au>SHRIVER, Craig D</au><au>PONNIAH, Sathibalan</au><au>PEOPLES, George E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2006-01-15</date><risdate>2006</risdate><volume>12</volume><issue>2</issue><spage>478</spage><epage>486</epage><pages>478-486</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: We studied serum monocyte chemotactic protein-1 (MCP-1) levels in breast cancer patients in relationship to their clinicopathologic
variables and immune response to a / neu E75 vaccine.
Experimental Design: We measured MCP-1 levels in 32 / neu + breast cancer patients before and after vaccination with a / neu E75 peptide + granulocyte macrophage colony-stimulating factor vaccine. Clinical prognostic variables were collected. Vaccine-specific
immunologic responses were monitored.
Results: Serum MCP-1 levels >250 pg/mL (MCP-high) correlated with favorable prognostic variables. MCP-high patients compared with
MCP-low (<250 pg/mL) patients showed statistically significant later onset of disease, earlier stage of disease, fewer nodal
metastasis, and less chemotherapy. MCP-high patients had increased levels of preexisting immunity when compared with MCP-low
patients (69% versus 21%; P = 0.02). However, MCP-low patients showed higher inducible levels of MCP-1 compared with MCP-high patients (median increase,
41% versus 0%; P = 0.001) after vaccination. Moreover, MCP-low patients with >50% increase in MCP-1 levels (response-high) had worse clinical
prognostic variables compared with patients with <50% increase (response-low). Response-high patients had statistically significant
more poorly differentiated tumors, later stage of disease, and higher percentage of large tumors. Patients with >30% postvaccination
MCP-1 increase also showed significant increases in E75-specific CD8 + T-cells (0.05% versus 0.38%; P = 0.03) in response to vaccination.
Conclusions: High serum MCP-1 levels in breast cancer patients correlate with favorable prognostic variables and increased preexisting
/ neu immunity. E75 vaccination induces the largest MCP-1 response in patients with unfavorable clinicopathologic variables. Therefore,
low serum MCP-1 levels may identify patients with worse prognosis and those most likely to benefit from this vaccination.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>16428490</pmid><doi>10.1158/1078-0432.CCR-05-1425</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2006-01, Vol.12 (2), p.478-486 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70696746 |
| source | MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Antineoplastic agents Biological and medical sciences Biomarkers, Tumor - metabolism breast cancer Breast Neoplasms - immunology Breast Neoplasms - prevention & control Cancer Vaccines - therapeutic use Chemokine CCL2 - metabolism Disease Progression Female Granulocyte-Macrophage Colony-Stimulating Factor - immunology Granulocyte-Macrophage Colony-Stimulating Factor - metabolism Gynecology. Andrology. Obstetrics Humans Immunity, Cellular Immunoconjugates Lymph Nodes - immunology Lymph Nodes - metabolism Lymph Nodes - pathology Mammary gland diseases MCP-1 Medical sciences Middle Aged Neoplasm Staging Peptide Fragments - immunology Pharmacology. Drug treatments Prognosis prognostic factors Receptor, ErbB-2 - metabolism Survival Rate tumor immunity Tumors |
| title | Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T03%3A50%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlations%20between%20Serum%20Monocyte%20Chemotactic%20Protein-1%20Levels,%20Clinical%20Prognostic%20Factors,%20and%20HER-2/neu%20Vaccine-Related%20Immunity%20in%20Breast%20Cancer%20Patients&rft.jtitle=Clinical%20cancer%20research&rft.au=DEHQANZADA,%20Zia%20A&rft.date=2006-01-15&rft.volume=12&rft.issue=2&rft.spage=478&rft.epage=486&rft.pages=478-486&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-05-1425&rft_dat=%3Cproquest_cross%3E70696746%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17476314&rft_id=info:pmid/16428490&rfr_iscdi=true |